The Industry Association

Who we are

Nuclear Medicine Europe (ex AIPES) is a European Industrial Association working on promotion, awareness and defence of Nuclear Medicine and Molecular Healthcare in Europe. We are active in the field of Imaging and Therapy with Molecular and Radioactive Tracers. The main objective of our association in this field is to ensure the promotion of the economic and/or commercial interests of its Members, in particular, by all means allowing to increase the awareness to the benefits of the products and services they offer.

In addition to the main activity described here above, our association may represent the common interest of the Members in relation with the European Institutions, with other national and international authorities and in dealing with other scientific, educational or professional association groups or societies, such as EANM, EFPIA, CERN.

The Association does not interfere in the activities of its Members.

The General Meeting is composed of all the Members of the Grouping. Each member shall appoint an authorized representative to attend and vote on its behalf at a General Meeting. The General Assembly adopts resolutions, elects Managers of the Association and agrees to the admission of new Members. The General Meeting is composed of appointed representatives from each Member or Associate partner of the Association. Each representative has one vote and resolutions shall only be adopted by unanimous consent.

The members of the Grouping can, by a written resolution taken by unanimous consent, take all decisions which are subject to the General Meeting, out of a meeting, except for those decisions for which the adoption before a notary must be provided. Following the adoption of a resolution, the Executive Committee shall ensure that the statutory filing requirements are complied with.

The representatives of the 2019-2022 AIPES General Assembly are :

Executive Committee

The business and administration of the Grouping is under the control of the Executive Committee which takes all steps necessary to attain the objectives of the Grouping. The Executive Committee is endorsed with the power, vis-a-vis third parties, to act in all manners for and on behalf of the Grouping.

The 2016 – 2019 Executive Committee is composed as follows:

antonis_130px

Antonis Kalemis

President
Bio

Antonis studied biomedical engineering, medical physics and business management, in Greece and the United Kingdom. After his PhD, he held R&D, marketing and business development positions in major companies within the radiopharmaceuticals and medical devices industries.

Since 2016, he is with Siemens Heathineers currently looking after its Molecular Imaging business for North Europe and West Africa. 

His involvement with AIPES/Nuclear Medicine Europe started in 2008 where he held different positions. He is passionate about education and raising awareness of what nuclear medicine can offer for patients and health systems. 

françois_130px

François Labarre

Vice President
Bio

François Labarre is the Vice President Northern Europe of the Curium SPECT commercial organization since 2018.

Involved in the Nuclear Medicine sector in Europe since 2001, he managed sales and marketing organizations successively for Amersham and Mallinckrodt up to 2009. He then moved to IBA Molecular as President for Europe until 2014.  François holds a degree in biochemistry and an executive degree from the ESCP Europe Business.

angel_130px

Angel Hijos

Vice President and Treasurer
Bio

Angel Hijos is Director of the European Manufacturing Operations on the Avid Radiopharmaceutical’s team, a Lilly owned company located in Philadelphia. In his role, Angel provides leadership, direction and management of Alzheimer’s radiotracers for clinical trials across the globe.

Angel, joined the Nuclear medicine world in 2013 with the commercialization of an innovative Beta Amyloid radiotracer across Europe. Supporting the Lilly Global Alzheimer team, he  interacts with key opinion leaders in Neurology and Nuclear medicine.

Angel gained a cumulative experience across Europe and USA within Lilly, a global pharmaceutical company he joined in 1990.

Since 2013, Angel supports the Lilly Global Alzheimer team. He directs the management and oversight of contract manufacturing organizations to ensure the just in time supply of Lilly’s radiopharmaceutical drugs. Angel Interacts across Europe with Key Opinion Leaders in Neurology and Nuclear Medicine. He is currently Director, European Manufacturing Operations at Eli Lilly.

Erich_130px

Erich Kollegger

Vice President and Secretary General
Bio

Erich Kollegger took over the General Management of the Institute for Radioelements (IRE) and its subsidiary IRE Elit early 2018. Engineer in Electro-Mechanics by education, his professional experience includes Project Management, as well as Production and Plant Management in chemical and pharmaceutical plants, in Belgium and France. Before joining IRE, Erich was Plant Manager of a manufacturing site for Baxter Healthcare in Lessines, Belgium. Erich is also Chairman of the Board of Directors of Transrad, a company specialized in transport of radioactive material.He is also President of the company Transrad specialized in transportation of nuclear material, and represents IRE as director of Sterigenics and Oncidium.
He is appointed lecturer at the Universities of Liège, Brussels and Louvain-la-Neuve in Belgium, being in charge of a course on Business management.

_gtb

Guy Turquet de Beauregard

Honorary President
Bio

Guy Turquet de Beauregard, who has been a member of the Executive Committee since 2008 and President of AIPES from 2013 to 2016, devoted his professional life to nuclear medicine and has always been a strong supporter of our industry became AIPES Honorary President. AIPES continues to benefit from his valuable advice and contacts in the scientific and political world.

NMEu Executive Office – Brussels

The administration office, based in Brussels, is in charge of coordination between stakeholders, and acts as a liaison office and an information platform between the Group and the other European entities.

_jbaldasso

Jocelyne Baldasso

Administrator
Bio

Based in the AIPES Executive Office – Brussels since 2006, Jocelyne Baldasso is in charge of the administration, the corporate activities and the coordination between the Board, the Working Groups and third parties.
Prior to that, she evolved in the field of contemporary art and acted as coordinator for the negotiations with governmental bodies for the realization of monumental sculptures and projects in the US, Asia and Europe.
Jocelyne has an extensive experience at corporate, governmental and executive levels within international companies and European Associations. She holds a degree in psychology of sciences of human behaviour (awarded in 1998)

david_130px

David Crunelle

Senior Communications Advisor
Bio

Mission Statement

NMEu Mission Statement

"Imaging & Therapy with Molecular and Radioactive Tracers"

Our Objectives:
1. Foster Innovation in nuclear medicine and molecular imaging;
2. Cooperate for appropriate regulations in all aspects of nuclear medicine missions;
3. Support and facilitate logistics and operations needs of our members;
4. Promote the value of nuclear medicine achievements;
5. Harmonization through Europe;
6. Simplification of rules and procedures.

NMEu’ Position on Radiopharmaceuticals: Three Pillars to Drive our Actions:

PATIENTS SAFETY

Full compliance: adoption of all relevant requirements, both on radioactivity and pharmaceuticals Compliance covers the entire process: from R&D, to manufacturing, to distribution, to any after sale events

INNOVATION

Tradition of innovation and commitment to novel, future tracers Development of new drugs will require a more tailored regulatory approach

HEALTHCARE FOR EVERYONE

Ensuring products and technology availability for millions of procedures all over Europe.

NMEU Code of Ethics

The sensitive nature of NMEU activities for the public, (i.e. human healthcare issues and radioactive hazards fear), implies at any time the risk of being the target of public inquiry and questioning. Moreover, NMEU wants to promote fair competition between its members. NMEU members should therefore at least fully comply with the EU and International legislation and principles related to:

  • Good Manufacturing Practice and Good Clinical Practice
  • Radioactive Transport Regulation
  • Radioprotection regulations for products or employees
  • Confidentiality of information
  • Patent protection
  • Fair Trade
  1. Each company should respect EU (and related EMEA and/or MDD guidelines) and local Good Manufacturing Practice (GMP) rules in the production of radiopharmaceuticals and medical equipment.
  2. Each company should respect EU (and related EMEA guidelines) and local GMP rules for the production of investigational Medical Products (IMP) for human use.
  3. IMP for human use should only be provided to customers within the framework of a clinical study or for compassionate use and, in any case, under the express authorization from the competent authority responsible for IMP for human use
  4. No company shall sell, distribute or transport products from producers which do not respect EU and local GMP rules for the production of radiopharmaceuticals and medical equipment.
  5. No company shall sell, distribute or transport Investigational Medical Products (IMP) for human use not produced in laboratories, which are not authorized for IMP.
  6. Each company should strictly respect ADR regulations (European Agreement concerning the International Carriage of Dangerous Goods by Road) when transporting radiopharmaceuticals and IMP.
  7. Regarding their employees and products, each company should comply with ICRP (International Commission on Radiological Protection) and local radioprotection rules in the production, distribution and transportation of radiopharmaceuticals.
  8. Each company should report to NMEU any event that could trigger a crisis communication plan from the NMEU Executive Committee, in particular in view of avoiding potential EU-wide negative impact for the industry and/or customers.
  9. Each company should respect confidentiality of information and documents shared within NMEU , during and from NMEU meetings. Such confidential information cannot, in any case, be used against any NMEU member.
  10. Each company should comply with patents regulation.

Emanating from the first clinical use of nuclear medicine tracers and therapeutics in the 1950s, a clinical discipline and supporting industry began to emerge during the 1970s in the United States, Europe and Japan. By 1985 this activity was considered appropriate for regulation by the European Union, and a directive bringing radiopharmaceuticals in line with all other drug substances was introduced.

In 1987, all interested radiopharmaceutical companies agreed to form the Association of Radiopharmaceutical Producers Europe (ARPE) which was formalised shortly afterwards as a European economic interest group (EEIG).
ARPE’s initial focus on pharmaceutical regulations was very successful and led to an agreement with the EEC for rational registration process. In addition to these activities ARPE also became a focal point for dealing with threats to the continuing success of radiopharmaceuticals in Europe. For example, a threat to disrupt supply of a key raw material in the production of radiopharmaceutical preparations was addressed by focussed lobbying with governments, regulators and industrial partners.

By the mid 1990s the professional organisation representing nuclear medicine physicians in Europe (EANM) provided an opportunity for ARPE to become directly involved in a strategic collaboration to develop the speciality. In order to appropriately respond to this challenge, ARPE broadened its statutes to encompass hardware and equipment companies and renamed itself the Association of Radiopharmaceutical Producers and Equipment Suppliers (ARPES). ARPES was closely involved with several EANM projects including the funding of a cost benefit study for nuclear cardiology and a contribution to the establishment of a strategic vision for nuclear medicine in Europe. By the end of the 1990s most members had broadened their scope and were now engaged in multi-modality in-vivo diagnostic activities.
To reflect this reality a new name AIPES (Association of Imaging Producers and Imaging Suppliers), with the mission to foster industry collaboration across all fields of in-vivo diagnosis, was adopted in 2001.

During its relatively brief history our industry association has experienced massive technological, commercial and regulatory change. Despite this change, our members remain committed to providing the highest standards of product and service excellence to physicians worldwide and ultimately the patients that they serve.

In May 2019, AIPES change its name and visual identity to become Nuclear Medicine Europe.

Shopping Basket